KR20080033500A - 정신분열증 및 기타 정신병의 치료를 위한 3,11ｂ 시스 디히드로테트라베나진 - Google Patents

정신분열증 및 기타 정신병의 치료를 위한 3,11ｂ 시스 디히드로테트라베나진 Download PDF

Info

Publication number
KR20080033500A
KR20080033500A KR1020087005308A KR20087005308A KR20080033500A KR 20080033500 A KR20080033500 A KR 20080033500A KR 1020087005308 A KR1020087005308 A KR 1020087005308A KR 20087005308 A KR20087005308 A KR 20087005308A KR 20080033500 A KR20080033500 A KR 20080033500A
Authority
KR
South Korea
Prior art keywords
dihydrotetrabenazine
cis
psychosis
compound
schizophrenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020087005308A
Other languages
English (en)
Korean (ko)
Inventor
앤드류 존 더프필드
Original Assignee
캠브리지 래버러토리스 (아일랜드) 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0516167.4A external-priority patent/GB0516167D0/en
Priority claimed from GB0516790A external-priority patent/GB0516790D0/en
Application filed by 캠브리지 래버러토리스 (아일랜드) 리미티드 filed Critical 캠브리지 래버러토리스 (아일랜드) 리미티드
Publication of KR20080033500A publication Critical patent/KR20080033500A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020087005308A 2005-08-06 2006-08-04 정신분열증 및 기타 정신병의 치료를 위한 3,11ｂ 시스 디히드로테트라베나진 Withdrawn KR20080033500A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0516167.4A GB0516167D0 (en) 2005-08-06 2005-08-06 Pharmaceutical compounds
GB0516167.4 2005-08-06
GB0516790.3 2005-08-16
GB0516790A GB0516790D0 (en) 2005-08-16 2005-08-16 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
KR20080033500A true KR20080033500A (ko) 2008-04-16

Family

ID=37400949

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087005308A Withdrawn KR20080033500A (ko) 2005-08-06 2006-08-04 정신분열증 및 기타 정신병의 치료를 위한 3,11ｂ 시스 디히드로테트라베나진

Country Status (20)

Country Link
US (1) US20110257220A1 (https=)
EP (2) EP1855677B1 (https=)
JP (1) JP2009504622A (https=)
KR (1) KR20080033500A (https=)
AT (2) ATE415968T1 (https=)
AU (1) AU2006277753B2 (https=)
CA (1) CA2620960A1 (https=)
CY (1) CY1108843T1 (https=)
DE (1) DE602006004009D1 (https=)
DK (1) DK1855677T3 (https=)
ES (1) ES2318771T3 (https=)
HR (1) HRP20090074T3 (https=)
MX (1) MX2008001549A (https=)
NZ (1) NZ566011A (https=)
PL (1) PL1855677T3 (https=)
PT (1) PT1855677E (https=)
RS (1) RS50807B (https=)
RU (1) RU2407743C2 (https=)
SI (1) SI1855677T1 (https=)
WO (1) WO2007017654A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2081929T3 (pl) 2006-11-08 2013-06-28 Neurocrine Biosciences Inc Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania
US8008500B2 (en) 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
US8053578B2 (en) 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
CA2801061A1 (en) 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
KR101882044B1 (ko) 2011-04-01 2018-07-25 쓰리엠 이노베이티브 프로퍼티즈 캄파니 트라이아진계 자외선 흡수제를 포함하는 필름
EA201691512A1 (ru) 2014-01-27 2017-01-30 Оспекс Фармасьютикалз, Инк. Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2
NZ760790A (en) * 2014-02-07 2022-11-25 Neurocrine Biosciences Inc Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
MY193767A (en) 2015-10-30 2022-10-27 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
CN108925135B (zh) 2015-12-23 2025-09-19 纽罗克里生物科学有限公司 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
TW202345829A (zh) * 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
WO2018140092A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
GB201705302D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
ES3024958T3 (en) 2017-09-21 2025-06-05 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2843591A (en) 1958-07-15 Method for preparing same
US2830993A (en) * 1958-04-15 Quinolizine derivatives
CA2058640A1 (en) * 1991-01-25 1992-07-26 Richard R. Scherschlicht Tricyclic pyridone derivative
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2770215B1 (fr) * 1997-10-28 2000-01-14 Pf Medicament Derives d'aminomethyl-benzo[a]quinolizidine, leur preparation et leur application en therapeutique pour les maladies neurodegeneratives
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
DE602006004009D1 (de) 2009-01-15
RS50807B (sr) 2010-08-31
SI1855677T1 (sl) 2009-04-30
PT1855677E (pt) 2009-01-13
CY1108843T1 (el) 2014-07-02
ATE415968T1 (de) 2008-12-15
HK1111083A1 (en) 2008-08-01
RU2407743C2 (ru) 2010-12-27
US20110257220A1 (en) 2011-10-20
ES2318771T3 (es) 2009-05-01
EP1855677B1 (en) 2008-12-03
CA2620960A1 (en) 2007-02-15
ATE534391T1 (de) 2011-12-15
NZ566011A (en) 2011-01-28
EP2050451A1 (en) 2009-04-22
EP2050451B1 (en) 2011-11-23
HRP20090074T3 (en) 2009-04-30
DK1855677T3 (da) 2009-02-09
JP2009504622A (ja) 2009-02-05
RU2008108623A (ru) 2009-09-20
MX2008001549A (es) 2008-04-04
EP1855677A1 (en) 2007-11-21
AU2006277753B2 (en) 2011-11-10
PL1855677T3 (pl) 2009-07-31
AU2006277753A1 (en) 2007-02-15
WO2007017654A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
KR20080033500A (ko) 정신분열증 및 기타 정신병의 치료를 위한 3,11ｂ 시스 디히드로테트라베나진
CN100591680C (zh) 二氢丁苯那嗪类及包含它们的药用组合物
CA2284732C (en) Analogs of cocaine
RU2409365C2 (ru) ПРИМЕНЕНИЕ 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИНА ДЛЯ ЛЕЧЕНИЯ СИМПТОМОВ БОЛЕЗНИ ГЕНТИНГТОНА
EP3503879B1 (en) Composition comprising (a) a dual agent acting as a 5-ht2a receptor antagonist and cyp2d6 inhibitor and (b) an nmda receptor antagonist for use in the treatment of diseases involving glucose
GB2463452A (en) Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463451A (en) 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
JP2011502977A (ja) 多発性硬化症および自己免疫性脊髄炎の治療における３，１１Ｂ−ｃｉｓ−ジヒドロテトラベナジンの使用
US20110190333A1 (en) Dihydrotetrabenanzine for the treatment of anxiety
EA020553B1 (ru) 7-([1,2,4]ТРИАЗОЛО[1,5-α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИЧЕСКИХ РАССТРОЙСТВ
JP2906339B2 (ja) 活性成分としてデヒドロエボジアミン−ＨＣｌを含有する記憶増強および抗痴呆剤
CN101351205A (zh) 治疗精神分裂症及其它精神病的3,11b-顺式-二氢丁苯那嗪
HK1111083B (en) 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
HK1125575A (en) 3,11b cis dihydrotetrabanezine for the treatment of psychoses
KR20070023666A (ko) 디하이드로테트라베나진 및 이를 함유하는 약학 조성물
ES2426915T3 (es) Diastereoisómeros de 4-ariloxi-3-hidroxipiperidinas
HK1098138B (en) Dihydrotetrabenazines and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080303

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid